06 Feb Call to Action From Your Partners at Triova!
Triova is committed to increasing awareness of the benefits of compounding and protecting patient access to compounded medications. December 29, 2016, the FDA released their final Guidance for Industry (GFI) under section 503A. This guidance prohibits office-use compounding, which is contradictory to the 2013 Drug Quality and Security Act (DQSA) that allows office-use compounding when authorized by state pharmacy laws. We believe that office-use compounding is a traditional and important aspect of pharmacy practice, and if prohibited will negatively affect patient care by restricting access to much needed medications and treatment options.